Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.

ABSTRACT:

Background

Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action.

Methods

Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35). Logistic regression analysis with remission as the dependent variable and treatment arm-by-BMI category interaction as the primary independent variable was used to evaluate if BMI differentially predicted response to escitalopram (SSRI) monotherapy, bupropion-escitalopram combination, or venlafa

SUBMITTER: Jha MK 

PROVIDER: S-EPMC6312180 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature